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Abstract
Studying associations among genes and diseases provides an important avenue for
a better understanding of genetic-related disorders, phenotypes and other complex
diseases. Research has shown that many complex human diseases cannot be at-
tributed to a particular gene, but a set of interacting genes. The effect of a specific
gene on multiple diseases is called pleiotropy and interactions among several genes
to contribute to a specific disease is called epistasis. In addition, many human ge-
netic disorders and diseases are known to be related to each other through frequently
observed co-occurrences. Studying the correlations among multiple diseases helps us
better understand the common genetic background of diseases and develop new drugs
that can treat them more effectively and avoid side effects. Meanwhile, network sci-
ence has seen an increase in applications to model complex biological systems, and
can be a powerful tool to elucidate the correlations of multiple human diseases as
well as interactions among associated genes. In this thesis, known disease-gene asso-
ciations are represented using a weighted bipartite network. Subsequently, two new
networks are extracted. One is the weighted human disease network to show the
correlations of diseases, and the other is the weighted gene network to capture the
interactions among genes. We propose two new centrality measures for the weighted
human disease network and the weighted gene network. We evaluate our centrality
measurements and compare them with the most commonly used centralities in bio-
logical networks including degree, closeness, and betweenness. The results show that
our new centrality methods can find more important vertices since the removal of
the top-ranked vertices leads to a higher decline rate of the network efficiency. Our
ii
identified key diseases and genes hold the potential of helping better understand the
genetic background and etiologies of complex human diseases.
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Chapter 1
Introduction
Genome-wide association study (GWAS) is one of the most important tools for inves-
tigating the genetic architecture of genetic-related phenotypes and human diseases [2].
Scientists have proposed many methods based on SNP (Single Nucleotide Polymor-
phisms) GWAS [3, 4] where SNP refers to a variation in a single DNA building block,
called a nucleotide. To find the SNPs that are associated with a disease, a standard
GWAS should investigate large number of people with the disease (case) and large
number of healthy people (control). GWAS includes two steps of discovery and val-
idation. In the first step, by investigating the cases and controls, researchers search
for SNPs that can best discriminate cases and controls. All SNPs are analyzed at
this stage and are ranked according to their significance levels. All SNPs that meet
a p-value threshold can go forward to the next step, validation [5].
Some diseases can be caused by a single mutation at a single gene. However, most
complex diseases are likely caused by interactions among a set of different genes,
called epistasis [6, 7]. Hence, finding the interactions among genes is critical for
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us in order to better understand the genetic mechanisms of diseases in the human
body [8]. Therefore, many researchers have changed their focus from considering the
susceptibility of a single locus [9] to the interactions among a set of loci [10]. However,
the huge number of SNPs cause extreme computational costs and subsequently some
restrictions on the use of SNP based methods [11].
Nowadays, the most common approach for identifying the interactions among
SNPs is based on statistical methods [12, 13, 14, 15, 16, 17], data mining approaches
[18, 19, 20], machine learning [21, 22], and other methods [23, 24]. Considering
the interactions among genes is not the only way to find genetic origins of complex
diseases, but the study of the correlation of diseases is a good tool for such a purpose.
During the past decades, significant progress has been made on our understanding
of human diseases [25]. However, the genetic architectures of complex diseases are
still largely unclear. Many common diseases tend to be related to each other, and
they may share a common genetic origin. Studying the correlations among multiple
diseases provides an important avenue to investigate the common genetic background
of diseases and has the potential for better elucidating the genotype to phenotype
mapping [26, 27], as well as better predicting disease association genes [28, 29, 30,
31, 32]. Furthermore, learning which diseases are correlated can help use of existing
drugs to treat multiple similar diseases [33, 34, 35, 36, 37].
Meanwhile, network-based analysis is a good way for utilizing and developing
network-related metrics and measurements to perform advanced analysis of biomed-
ical data. Network science is a rising field where entities and their complex relation-
ships are studied on a global scale [38, 39, 40], and has seen increasing applications for
performing advanced analysis on biomedical data [41, 42, 43, 44, 45, 46]. There are
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various cellular components in the human cells that interact with each other within
the same cell or across different cells [39]. A network called the human interactome can
be constructed according to the interactions of those different cellular components.
Each component can be represented as a vertex in the network and interactions among
them can be captured as links (or edges) connecting pairs of the cellular components.
There are a few types of interactome networks such as a molecular network, which
has been studied a lot in recent years. This type of interactome network is based on
the interactions among proteins where the vertices are proteins and there is a link
between two vertices if there is a physical interaction between corresponding proteins
[47, 48, 49]. Another type of interactome network is called the metabolic network
where vertices are metabolites and a link connects two metabolites if they partici-
pate in the same biochemical reactions [50, 51, 52]. There are some other types of
interactome networks, such as regulatory [53, 54] and RNA networks [55, 56].
Considering genes and diseases as vertices in the interactome networks, as well as
the links connecting the vertices in such networks help us address some features of the
genes which are related to genetic phenotypes and complex diseases [39]. Theoretical
tools including graph theory and the branch of mathematics that is related to networks
such as probability and statistics can be used to analyze networks [57]. For example,
the link weights in the gene networks can be interpreted as the strength of interaction
among genes. The number of neighboring vertices connected to a vertex shows the
importance of that vertex. By using some sophisticated centrality measures, the most
important vertices in the network can be identified more precisely. The most common
centrality measures include degree, closeness, and betweenness centralities [57].
In this thesis, we propose a new method for the construction of a weighted human
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disease network (WHDN) and a weighted gene network (WGN). In addition, we
propose two new centrality measures to identify the most important diseases and
genes. First, we use a large database of disease-gene associations to build a weighted
bipartite disease-gene network and then construct the WHDN, where link weights
capture the strength of the pairwise disease correlations. In the same manner, we
construct the WGN where link weights refer to the strengths of the pairwise gene-gene
interactions. After the backbone extraction of the WHDN and the WGN, we design
a centrality measure specifically for the context of the WHDN that considers not only
the degree of a vertex but also the importance of its incident edges. Then, we extend
the proposed centrality measure upon application to the WGN. In both networks,
we compare our new centrality measures with degree, closeness, and betweenness by
evaluating the network efficiency decline rate with the removal of top-ranked vertices
by each centrality measurement. From the WHDN, we find the most important and
central diseases with their most correlated disease. From the WGN, we identify the
most important genes with the gene that has the strongest interaction with them.
Important vertices, in this study, refer to the vertices that by removing them from
the networks, the network efficiency will be declined. We also find the diseases that
have the strongest association with the top-ranked genes in the WGN.
The rest of thesis is organized as follows. In the next section, some related studies
are discussed. In section 3, we describe the construction, reduction, and properties
of the networks. In this section, we discuss the disease-gene associations that we
used to construct the bipartite disease-gene network, the weighted human disease
network, and the weighted gene network. Our new proposed centrality measurements,
comparison, and evaluation are given in section 4, followed by discussion in section 5.
4
Chapter 2
Literature Review
2.1 Complex Network Analysis for Human Dis-
ease Studies
Biological networks have been studied extensively in recent years. In this section,
we discuss some related studies in which authors use complex network analysis on
the biomedical dataset for different purposes. In this section, we can see the role
of complex networks analysis on interpreting biomedical concepts and extracting the
meaningful information based on web-based methods and technologies.
Oti et al. [49] used a PPI (Protein-Protein Interaction) network for predicting
disease genes. Wu et al. [58] integrated PPI networks with gene expression data in
order to rank disease genes associated with various cancers. They showed that their
method was able to find replicable high-rank genes using different datasets. Vazquez
et al. [59] used the protein-protein interaction network to assign a function to a unas-
signed protein. The idea is assigning the most common function(s) belonging to the
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classified interacting proteins to an unclassified protein. Hu et al. [60], constructed
a network based on interactions among SNPs. Then, they ranked all pairwise in-
teractions to extract a statistical epistasis network. Only those interactions whose
strength was higher than a certain threshold were included in the epistasis network.
As a result, 36 new SNPs related to bladder cancer were found. They showed that the
statistical epistasis network shows significant properties of the genetic architecture of
bladder cancer. O¨zgu¨r et al. [61] used network-based measures such as degree, close-
ness, and betweenness centralities to rank genes in a gene-gene interaction network.
Based on the ranked genes, they identified gene-disease associations. The results
showed that the top 20 important genes ranked by network centrality measures are
related to prostate cancer. Some important genes selected by closeness and between-
ness measurements, whose relation with the diseases is unknown, were interpreted as
candidate genes for future experimental studies. Cho and Zhang [62] proposed a new
algorithm for extracting a hidden hub-oriented tree structure from an interactome
network by calculating functional similarities among proteins. The results showed
that the selected hubs are significant proteins in the yeast protein network.
Some studies aimed at identifying the correlations among diseases through network
analysis [39, 63, 64]. Lee et al. [65] constructed a network where the vertices are
diseases; the goal of the study was to find disease comorbidity, which can help predict
and prevent diseases. Goh et al. [66] constructed a human disease network (HDN)
by connecting pairs of diseases when they share common association genes. Of 1,284
diseases in the HDN, 867 have at least one link to other diseases, and 516 form a
giant component, suggesting that the genetic origins of most diseases, to some extent,
are shared with other diseases. Moreover, the HDN naturally and visibly clustered
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according to major disease classes such as the cancer cluster and the neurological
disease cluster. Basic network-based measures show that cancer and neurological
disorders have high genetic locus heterogeneity which causes a similar phenotype by
the mutation in different loci [67]. Human disease networks provide scientists with
a genome-wide roadmap for future investigations of the correlations among diseases.
Researchers can visually find the correlation among diseases and associations among
disease genes and diseases. To test the robustness of results obtained in this article,
the author expanded the disease genes from 1,777 to 2,765 genes in which the newly
added disease genes have unidentified mutation links [68]. The results have confirmed
that the backbone of previous findings is still preserved, which shows the robustness
of the results. Zhou et al. [69] extracted over twenty million bibliographic records
from PubMed [70] in order to obtain 147,978 connections between 322 symptoms and
4,219 diseases. A human symptoms-disease network (HSDN) was then constructed
and could show the symptom similarity between all pairs of diseases (7,488,851 links)
in the network. The weight of a link represented the similarity of symptoms between
two diseases. They showed that the correlations among diseases were significantly
related to the genetic associations that each pair of diseases had in common as well
as the interactions between their related proteins. Lee et al. [65] built a disease
metabolism network in order to study disease comorbidity for better disease prediction
and prevention. In this study, two diseases are connected with each other if a mutated
enzyme catalyzes a metabolic reaction between them. Their results show that diseases
with higher degrees, i.e., connecting with many other diseases, have a higher rate of
prevalence and mortality.
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2.2 Centrality Measures
Finding the most important vertices in the networks is one of the most challenging
problems. Different methods rank the vertices from different point of views. Some
methods just use local information to rank vertices and some other use global infor-
mation. Some methods are designed for weighted graph and some other is defined for
unwaighted graphs. Reasearchres are trying to rank the vertices in the network based
on differnet properties of networks. In this section, we discuss the most commonly
used centrality measures followed by recently proposed vertex centrality measures.
2.2.1 The Most Commonly Used Centrality Measures
2.2.1.1 Degree
Degree centrality refers to the total number of connections that a vertex has in the
networks. In the context of network science, the more connections a vertex has,
the more important that vertex is. Although degree centrality is a good measure to
quantify the importance of vertices in the networks according to the direct connections
the vertices have, it still suffers from a lack of contribution in the context of large
scale structures. In other words, a vertex may not have a high degree in the network,
but because of its connection to other vertices with high degrees, it may be considered
important as well.
2.2.1.2 Closeness Centrality
The next most important measure in the network theory is closeness centrality, which
is a good measure to specify the importance of the vertices in terms of their mean
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distance to all other vertices in that network [57]. Most network-based methods used
for the analysis of data are built on direct interactions among vertices. Recently,
indirect connections have drawn increasing attention. These connections describe the
closeness of vertices in a network rather than relying on direct interactions [2]. The
closeness centrality is defined as follows [57]:
Ci =
n∑
j dij
(2.1)
where dij is the length of shortest path between the vertex i and the vertex j, and
n is the number of vertices in the network. Although closeness centrality is a good
measure to compute the centralities of vertices, this measure suffers some drawbacks.
It is only usable in a connected network because the minimum distance from a vertex
to other vertices from independent components is infinite. Therefore, the minimum
distance is meaningless in the networks with multiple disconnected components.
2.2.1.3 Betweenness Centrality
Another popular centrality measure is betweenness centrality, which measures the
extent to which a vertex located on the shortest paths of all pairs of other vertices.
Suppose we want to distribute a message to all persons in a social network. The goal
is distributing the message from vertex to vertex through the shortest paths. The
number of shortest paths a vertex lies on is called betweenness centrality, which is
defined as follows [57]:
xi =
∑
st
nist
gst
(2.2)
where nst is the number of the shortest paths from s to t that vertex i lies on, and
gst is the total number of the shortest paths from vertex s to vertex t. A drawback
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of betweenness centrality is that a vertex has a score of 0 if it does not lie on the
shortest path between any vertex pair. Therefore, it is possible that a significant
portion of vertices in a network have a betweenness centrality of 0, which means that
it is impossible to distinguish their importance.
2.2.2 Recently Proposed Vertex Centrality Measures
Measuring the centrality of vertices helps identify important vertices in the network.
The most common centrality measures include degree (the total number of neighbors),
closeness (the total distance to all other vertices), and betweenness (the fraction of
locating on the shortest paths of all pairs of vertices) [57]. Despite wide applications
in biological networks, these centrality measures are rather general and may not be
able to capture all the properties of vertices in the context of biological networks.
Therefore, carefully tailored centrality measures are needed for specific networks of
interest.
Ko¨hler et al. [71] proposed a vertex importance measure for disease genes in the
context of PPI networks. They used a random walk strategy to assess the distance
between vertices in the network, and reported improved performance compared with
conventional distance-based centrality measures.
Martinez et al. [72] proposed a generic vertex prioritization method using the idea
of propagating information across data networks and measuring the correlation be-
tween the propagated values for a query and a target set of entities. The authors
tested their method by ranking disease genes associated with alzheimer’s disease,
diabetes mellitus type 2 and breast cancer. They reported some new high-rank asso-
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ciation genes that could bring new insights into the study of the diseases.
Liu et al. [73] proposed a new method for finding bridge vertices in the network
in terms of their importance. Their proposed method is based on calculating the
line/edge importance. One of the most significant aspects of this method is using
local information instead of gathering global information, which results in reducing
computational costs and complexity compared to other common measures such as
CC (Closeness Centrality) and BC (Betweenness Centrality). For evaluating the
correctness of the proposed method, two different approaches were used. The first
approach was the transmission dynamic and the second approach was based on the
fault tolerance of the network in the absence of a vertex, meaning that the efficiency of
the network was measured after removing a vertex. The lower efficiency of a network
after removing a vertex, the more important the removed vertex is.
Nitsch et al. [74] provided a web-based tool for giving priority to genes in a genome-
wide PPI network. The method is based on the differential expression which each
vertex has with its neighbors. The idea is that a vertex with neighbors that have more
differentially expressed genes is more likely to be an important vertex. The random
walk method [75] was used in the proposed method. Both differentially expressed
genes and the strength of the interactions contribute to the importance of a vertex.
Therefore, a vertex with weak interactions may have a high importance because of
the high differential expression the vertex has with its neighbors.
Hu et al. [76] determined the importance of vertices in an unweighted network. The
proposed method called “vertex importance contribution correlation matrix (NICCM)”
was compared with some basic vertex importance measures in network theory, such
as degree centrality and betweenness centrality, as well as newly developed methods
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like “vertex importance contribution matrix (NICM)”, proposed by Xujing [77]. The
most interesting point of the NICCM method is that both neighboring vertices and
the neighbors of the neighbors in the network unevenly contribute to the importance
of the vertices where the NICM method is just based on the directly connected ver-
tices. Another point is that there is an initialized importance score for each vertex,
which is calculated as the shortest distance between the vertex and all other vertices.
Nie et al. [78] used the information entropy concept to quantify vertex importance
in complex networks. Their proposed method, called “Mapping Entropy (ME)”,
specifies how much a vertex in the network correlates with its neighbors. One of the
advantages of this method is that it uses the local information to find the correlation
of a vertex with its neighbors instead of global information. Their results have shown
that the proposed method outperforms both degree and betweenness centralities.
Opsahl et al. [1] considered both vertex degree and the weight of edges together
while calculating vertex importance. The focus of this method is not only on the
number of links each vertex has but also on link weights. The idea can be given in
an example where the score of the importance of a vertex is ten. This score can be
given to a vertex with ten neighbors which have a link weight of one each, or for a
vertex with one neighbor with a link weight of ten, or any combination of these states
which results in ten. The goal of the article proposed by Opsahl [1] is to find the most
important vertices in the networks based on making a balance between the number
of links a vertex has and its link weights.
Yan et al. [79] proposed a new measure of vertex centrality in the weighted net-
work. The method, called C-index, measures the collaboration competence of a vertex
in such a network. The collaboration competence of a vertex depends on the number
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of neighbors of the vertex, the link weights incident to the vertex, and the importance
of the neighbors. The basic idea of the C-index is based on the H-index, which was
proposed by Hirsch [80]. The H-index gives an index, H, which shows the amount
of achievement a scientist has. The number of a scientist’s articles and the amount
of citations in each paper contribute to the H-index. The most important aspect of
the C-index method is that it uses some different factors to measure the collabora-
tion competence of a vertex like the number of edges, edge weights, as well as the
collaboration competence of collaborators themselves. In the proposed method, the
total sum of link weights in a weighted network is defined as vertex strength, where
the weight of edges captures the edge importance.
There are some different views for considering a vertex as the most important
vertex in the network. One argument is that a vertex with the highest weighted
links is the most important one, while another argument is that a vertex with the
highest number of links is the most important. Alternatively, another view is that a
vertex with the highest total sum of link weights is the most important vertex in the
network. Many studies have been done to find the most important verticies based on
different masures and techniquies by researchers. Specifically, in this study, the most
important vertices refers to those which reduce the network efficiency after removing
them from the networks.
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Chapter 3
Network Construction
3.1 Dataset
The data used in this project contains disease-gene associations (DGAs) from multi-
ple curated databases including UNIPROT, the comparative toxicogenomics database
(CTD) (human subset), PsyGeNET, Orphanet, and human phenotype ontology (HPO).
The disease-gene association data are conducted by DisGeNet group, available on Dis-
GeNET v4.0 [81]. The current version of the dataset contains 130,821 DGAs, between
13,075 diseases and 8,949 genes. Each DGA is assigned a score aki , for disease i and
gene k, within the range of [0,1] based on its level of evidence, the number and the
type of database sources supporting the DGA, and the number of publications veri-
fying the association between the gene and the disease [81]. The formula to compute
the GDA score is given below [82]:
a = C +M +
3∑
k=1
Lk (3.1)
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where:
C =

0.6 ifNsourcesi > 2
0.4 ifNsourcesi = 2
0.2 ifNsourcesi = 1
0 otherwise
where:
Nsourcesi is the number of CURATED sources supporting a DGA
i ∈UNIPROT, CTD, PSYGENET, ORPHANET, HPO
M =

0.16 ifNmodels = 2
0.08 ifNmodels = 1
0 otherwise
where:
Nmodels is the number of animal models for a DGA Models ∈ Rat, mouse from the
rat genome database (RGD), the mouse genome database (MGD), and CTD
L =

0.08 if
Ngd ∗ 100
Nliterature
≥ 0.08
Ngd ∗ 100
Nliterature
if
Ngd ∗ 100
Nliterature
< 0.08
15
where:
Ngd is the number of publication supporting a DGA in the source k.
Nliterature is the total number of publication in the source k.
The first step in the project is to clean up the data in order to ensure that
all diseases and genes in the dataset are unique and that there is no replication
of disease-gene associations. Next, since some diseases and phenotypes overlap we
only consider diseases in this study and remove all phenotypes from the dataset. We
keep diseases and syndromes in the dataset for our analysis and remove injuries or
poisonings, anatomical abnormalities, acquired abnormalities, mental or behavioral
dysfunctions, signs or symptoms, findings, congenital abnormalities, neoplastic pro-
cesses, and pathologic functions. We use DisGeNet web-based application [81] for
this filtering.
3.2 Bipartite Disease-Gene Association Network
The best representation for depicting the associations among genes and diseases is a
bipartite graph, which is called the disease-gene association network in this research.
The bipartite graph contains two disjoint sets of vertices. One set represents diseases
and another one represents genes. By definition, no edge is allowed to connect a pair
of vertices in the same set of vertices in a bipartite graph. That is, there can be no
link either between a pair of diseases or a pair of genes. There is an edge between a
gene and a disease if there is an association between them. Link weights are given by
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Figure 3.1: An example subgraph of the human disease-gene association network. The
bipartite network has two sets of vertices, i.e., genes and diseases, represented by rectangle
and gray ellipses, respectively. An edge connects a disease and a gene if there is a known
association between them. The weight of an edge indicates the strength of the DGA aki
between disease i and gene k.
scores computed by the GDA method in the original dataset. A sample subgraph of
the network is shown in figure 3.1.
Figure 3.2 depicts the degree distributions of diseases and genes in the bipartite
disease-gene association network. For the set of diseases, the maximum degree is
564, of the disease epilepsy, and the average degree is 5.43. In Figure 3.2 a), the
degree distribution of the diseases is right-skewed and approximately follows a power
law distribution, indicated by the straight linear fit on a log-log scale. For the set
of genes, the maximum degree is 111, of the gene LMNA, and the average degree is
5.81.
The bipartite network is comprised of multiple connected components with a single
17
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Figure 3.2: Degree distribution of a) diseases and b) genes in the bipartite disease-gene
association network. The distributions are shown on a log-log scale.
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Figure 3.3: The size distribution of the connected components in the bipartite disease-gene
network. The network has a single giant component with 10,212 vertices, and the majority
of other connected components are of size two, i.e., consisting of only one disease and one
gene.
giant component. Figure 3.3 shows its distribution of the size of connected compo-
nents. The giant component has 10,212 vertices consisting of 5,278 diseases and 4,934
genes. Apart from the giant component, all other connected components are small
with a size varying from two to nine, and most of them are only single pairs of one
disease and one gene. Since we are interested in investigating the large-scale genetic
correlations of human diseases as well as large-scale interactions among genes, we
focus the giant component of the disease-gene bipartite network in the subsequent
analyses.
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3.3 Weighted Human Disease Network (WHDN)
We construct the weighted human disease network (WHDN) using the giant connected
component of the bipartite disease-gene network. We use D and G to denote sets
of 5,278 diseases and 4,934 genes respectively in the giant connected component. In
the WHDN, an edge links two diseases i and j if they have at least one association
gene in common, and the weight of the edge, wij, is computed based on the number
of shared association genes, as well as the strengths of those associations.
Such a weight definition is inspired by Newman’s study on scientific collabora-
tion networks [38], where vertices are scientists and two scientists are connected by
an unweighted edge if they have coauthored one or more scientific papers together.
To define the strength of the tie between two connected scientists, two factors are
considered. First, two scientists whose names appear on a paper together with many
other coauthors know one another less well on average than two who are the sole
author of a paper. Thus, the collaborative ties are weighted inversely according to
the number of coauthors of a paper. Second, authors who have written many papers
together will know one another better on average than those who have written few
papers together. Thus, all coauthored papers are added up to account for the tie
strength of two scientists.
Here, similarly, we consider that the correlation of two diseases through a gene is
stronger when they are the only associated diseases with this gene than when there are
many other diseases associated with the same gene. The correlation of two diseases
is also considered stronger when they share more genes through stronger associations
than fewer genes or weaker associations. Thus, we extend Newman’s method to the
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weighted graph and define the weight of edge wij between two diseases i and j as
wij =
∑
k∈G
δki δ
k
j (a
k
i + a
k
j )
sk
, (3.2)
where δki is one if disease i and gene k have a DGA, and zero otherwise. a
k
i is the
score of their DGA assessed by DisGeNET as discussed in the previous section, and
sk is the strength of gene k as a vertex in the bipartite disease-gene network, defined
as the sum of the scores of the DGAs between gene k and its directly linked diseases,
sk =
∑
i∈D
aki . (3.3)
Such a weight definition indicates that the correlation strength of two diseases is
weighted inversely according to the strengths of the genes they share, and is propor-
tional to the total number of genes they share and the strengths of their DGAs.
For example, in Figure 3.1, the weight between diseases contact dermatitis (CD)
and white sponge nevus 1 (WSN1) is calculated as follows,
wCD,WSN1 =
∑
k∈G
δkCDδ
k
WSN1(a
k
CD + a
k
WSN1)
sk
=
aKRT4CD + a
KRT4
WSN1
sKRT4
=
0.2 + 0.48
0.881
= 0.7718.
Note that the weight of two diseases can be greater than one when they share mul-
tiple genes. For example the weight between diseases WSN1 and hereditary mucosal
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Leukokeratosis (HML) is calculated as follows,
wWSN1,HML =
∑
k∈G
δkWSN1δ
k
HML(a
k
WSN1 + a
k
HML)
sk
=
aKRT4WSN1 + a
KRT4
HML
sKRT4
+
aKRT13WSN1 + a
KRT13
HML
sKRT13
=
0.48 + 0.201
0.881
+
0.2 + 0.2008
0.6008
= 0.7729 + 0.6671
= 1.44.
Since the WHDN is constructed using vertices from the giant component of the
bipartite disease-gene association network, it only has a single connected component
with all 5,278 vertices in the disease set D. Two vertices have an edge connecting
them if the represented two diseases have at least one shared gene, and the edge
weight is assessed as described above. The WHDN has 112,342 edges and an average
vertex degree of 42.56. That is, a disease correlates with on average 42.56 other
diseases with varying strengths.
3.4 Weighted Gene Network (WGN)
To construct the weighted gene network (WGN), we use the method proposed in the
previous section. The idea of making a connection between a pair of genes and giving
weight to the link is the same. The difference is in the definition of the network where
in the WGN, an edge links two genes i and j if they are associated with at least one
common disease, and the weight of the link, wij, is computed based on the number
of shared association diseases, as well as the strengths of those associations.
The new extracted gene network is a single connected component because it is
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constructed from the giant component of the bipartite disease-gene association net-
work. Therefore, the number of individual genes is the same as the number of genes
in the gene set G of the bipartite graph, 4,934 vertices. Two vertices have a link con-
necting them if the represented two genes have at least one shared disease, and the
link weight is assessed as described in the previous section. The WGN has 711,748
links and an average vertex degree of 288.5. That is, a gene interacts with on average
288.5 other genes with varying strengths.
3.5 The Multi-Scale Backbone of Networks
Figures 3.4 and 3.5 depict the distribution of all the edge weights in the WHDN and
the WGN, respectively. As shown in this figure a large number of edge weights are of
small values and may not be particularly interesting for subsequent analysis. Those
weak edges not only add computational overhead to the network analysis, but also
render the network difficult to interpret. So, we perform an edge reduction and only
extract the most meaningful structure of the network.
3.5.1 Method
The most straightforward strategy for network reduction is to use a global weight
threshold and remove all links that have weights lower than the threshold. How-
ever, such a global thresholding strategy is somewhat arbitrary and may overlook
the network information present below the cutoff scale. To preserve the multi-scale
backbone of the weighted human disease network (WHDN) and the weighted gene
network (WGN) while removing less relevant and meaningful edges, we use a multi-
23
0 5 10 15 20 25
Weight
100
101
102
103
104
105
Fe
re
q
u
e
n
cy
Figure 3.4: Distribution of edge weights in the WHDN. The weight of an edge quantifies
the shared genetic background of two connected diseases. There are 112,342 edges in the
graph with weights ranging from 0.0152 to 22.4506.
scale filtering method proposed by Serrano et al. [83]. The backbone of networks
means the overall structure and topology of the networks.
First, the weights of edges linking vertex i with its neighbors can be normalized
as
pij =
wij
si
(3.4)
where si is the vertex strength, i.e., the sum of weights incident to vertex i, given by:
si =
∑
j∈Γ(i)
wij (3.5)
where Γ(i) is the set of vertex i’s neighbors. Therefore, there are two different nor-
malized values for a link eij using the strengths of its two end vertices si and sj as
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Figure 3.5: Distribution of edge weights in the WGN. The weight of an edge quantifies
the strength of interaction between two genes. There are 711,748 edges in the graph with
weights ranging from 0.0062 to 7.7856.
the denominator.
Second, a null model is introduced to inform us about the random expectation
for the distribution of weights associated with the connections of a particular vertex.
That is, the normalized weights pij that correspond to the connections of a certain
vertex of degree k are produced by a random assignment from a uniform distribution.
Thus the probability density function for one of these variables taking a particular
value x is
p(x)dx = (k − 1)(1− x)k−2dx. (3.6)
Then, Formula (3.7) is used to identify whether the probability, βij, of link weight
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pij is compatible with the null model with a threshold β.
βij = 1− (k − 1)
∫ pij
0
(1− x)k−2dx < β (3.7)
All links with βij lower than β are preserved in the network. Note that each
edge has two different values βij and βji. For solving this problem, OR and AND
rules can be used. Under the first rule, if either βij and βji is lower than β, the link
will be preserved. In the second case, an edge is preserved if both βij and βji are
lower than β. Darabos et al. [84] empirically found that the AND rule preserves the
network features better than using the OR rule in the context of human phenotype
networks. In this project, the AND rule is adopted to reduce the size of the networks
by removing the links which are less relevant.
To find the best cutoff for β, we calculate clustering coefficient, percentage of
remaining vertices and links, and total weight of the networks after applying a β
cutoff while β changes from 0 to 1.
3.5.2 Results
Figure 3.6 show the results as a function of the percentage of remaining links in the
WHDN and the WGN since we aim at removing as many links as possible while
preserving the multi-scale backbone of the original weighted networks. We choose a
β cutoff when the clustering coefficient and the remaining vertices and weights are
maximally preserved while as many links are removed as possible. Accordingly, the
cutoff β = 0.501 and β = 0.42 can be determined for the WHDN and the WGN,
respectively, shown as the intersection of the vertical dashed line and the β curve in
the figure.
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Figure 3.6: Choosing the β value for a) disease network and b) gene network. CC represents
clustering coefficient, %Vertices is the percentage of remaining vertices, %Weights is the
percentage of weights left after removing links, and %Links is the percentage of remaining
links.
After the backbone extraction, the WHDN has 4,898 vertices and 38,275 edges
and there are 4,640 vertices and 149,063 edges in the WGN. Those vertices are no
longer connected by a single component.
Figure 3.7 shows the size distribution of connected components in the WHDN
and the WGN. For the WHDN, there is a giant component with 4,810 vertices while
the giant component in the WGN has 4,608 vertices. Degree distribution of giant
components in the networks are shown in Figure 3.8. Again the degree distributions
are heavy-tailed and resembles a power-law relationship. The vertex epilepsy has the
highest degree of 576 in the WHDN and the highest degree 532 belongs to vertex
ERCC6 in the WGN. These giant components will be the focus for our next step
analysis, i.e., measuring vertex importance in order to find the most central diseases
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in terms of correlating with other diseases and the most central genes in terms of
interacting with other genes.
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Figure 3.7: The size distribution of connected components in the extracted backbone of
the a) the WHDN and b) the WGN. The WHDN has a single giant component with 4,810
vertices while there are 4,608 vertices in the giant component of the WGN.
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Figure 3.8: Degree distribution of vertices in the giant component of the extracted backbone
of a) the WHDN and b) the WGN. The distributions are shown on a log-log scale.
28
Chapter 4
Measuring Vertex Importance in
Networks
4.1 Measuring Vertex Importance in WHDN
4.1.1 Proposed Method (DIL-W)
We introduce a vertex importance measure for the weighted human disease network
(WHDN) by extending a centrality measure for unweighted networks proposed by
Liu et al. [73]. This measure assesses the centrality of a vertex based on both its
degree and the importance of its incident links (DIL centrality). For its extension on
weighted graphs, we name it the DIL-W centrality.
First, in the context of unweighted graph, the importance of a link eij that connects
vertex vi and vj can be calculated as follows:
Ieij =
Ueij
λeij
, (4.1)
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Figure 4.1: An example weighted graph.
where Ueij = (ki− t−1)(kj− t−1) and λeij = t2 +1. Following the convention, ki and
kj are the degrees of vertex vi and vj, respectively, and t is the number of triangles
with one edge being eij. The contribution that vertex vi makes to the importance of
eij is computed as
Cvivj = Ieij ×
ki − 1
ki + kj − 2 , (4.2)
where j ∈ Γi, and Γi is the neighborhood of vertex i.
Then, the DIL centrality of vertex vi is calculated by combining both its degree
and the importance of its incident links,
DILvi = ki +
∑
vj∈Γi
Cvivj . (4.3)
For weighted networks, we modify the computation of U in Equation (4.1) as
Ueij = (si − pi)× (sj − pj), (4.4)
where si is the strength of vertex vi, calculated by Formula (3.5), and pi is the sum
of link weights incident to vertex vi that form triangles with eij. This follows the
intuition that first an edge is considered more important when its two end vertices
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have higher strengths. Second, the importance of an edge is reduced when it has
alternative two-hop paths connecting the same set of end vertices. Therefore, we
subtract pi from si in Equation (4.4).
We define λ for weighted graphs as
λeij =
pi + pj
2
+ 1. (4.5)
Finally, the importance of a vertex can be measured by
DIL-Wvi = si +
∑
vj∈Γi
Cvivj , (4.6)
where Cvivj is defined as
Cvivj = Ieij ×
si
si + sj
. (4.7)
As an example, in the weighted graph given in Figure 4.1, vertex a has a higher
strength but a lower degree than vertex b. We compute their DIL-W centralities and
investigate which one is more central when both factors are considered.
First we have their strength values sa = 0.9 + 0.3 + 0.5 + 0.6 = 2.3, and sb =
0.2 + 0.11 + 0.2 + 0.7 + 0.5 = 1.71. Their neighborhoods are Γa = {b, c, d, g} and
Γb = {a, c, e, f, g}. For vertex a,
∑
vj∈Γa
Cavj = Cab + Cac + Cad + Cag,
where
Cab = Ieab ×
sa
sa + sb
,
and
Ieab =
Ueab
λeab
=
(sa − pa)× (sb − pb)
pa+pb
2
+ 1
.
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We have
pa = wac + wag = 0.3 + 0.6 = 0.9,
and
pb = wbc + wbg = 0.2 + 0.7 = 0.9.
So
Cab =
(sa − pa)× (sb − pb)
pa+pb
2
+ 1
× sa
sa + sb
=
(2.3− 0.9)× (1.71− 0.9)
0.9+0.9
2
+ 1
× 2.3
2.3 + 1.71
= 0.3423
We can also have
Cac = 0.3285, Cad = 1.4878, and Cag = 0.4312.
Then
DIL-Wa = sa +
∑
vj∈Γa
Cavj
= 2.3 + (0.3423 + 0.3285 + 1.4878 + 0.4312)
= 4.8898.
Similarly, we can compute the DIL-W centrality of vertex b as DIL-Wb = 2.8916.
Based on both the degree and importance of incident edges, vertex a is considered
more important than vertex b.
We apply the DIL-W centrality measurement to the giant component of the back-
bone of the WHDN, the distribution is shown in Figure 4.2. The DIL-W scores have
a high dynamic range, from 0.0610 to 80688.1129. The majority of the vertices have
low scores and a few number of vertices have scores that are greater by orders of
magnitude.
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Figure 4.2: Distribution of the DIL-W centrality in the giant component of the WHDN on
a log-log scale.
4.1.2 Results
We compare our DIL-W measurement with three most commonly used centralities,
degree, closeness, and betweenness, when applied to the giant component of the
backbone of the WHDN. For weighted graphs, degree centrality is calculated as vertex
strength given by Equation (3.5). Closeness and betweenness are shortest-path-based
centralities. Shortest path computation can be extended for the weighted graph as
follows,
dwij = min(
1
wih
+ ...+
1
whj
). (4.8)
Here dwij denotes the weighted distance between vertex i and j, and wih is the weight
of the edge linking vertex i and h. Since in our WHDN edge weight is strength,
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the distance between two vertices is the minimum sum of the inverse of edge weight
along the path connecting them. Once the weighted distance is defined, closeness and
betweenness can be calculated by their original definitions.
Figure 4.3 shows the correlation of DIL-W scores with a) degree, b) closeness, and
c) betweenness centralities. As we can see, there is a positive correlation between
the DIL-W measure and all three vertex centrality measures. The Spearman’s rank
correlation coefficient is 0.672 comparing DIL-W with closeness, is 0.71 comparing
DIL-W with betweenness, and is 0.947 comparing DIL-W with degree.
To evaluate our new vertex importance quantification method, DIL-W, we mea-
sure the network efficiency before and after we remove the most important vertices
in the WHDN. We calculate the decline rate of network efficiency after removing m
top-rank vertices. The network efficiency [85] is computed based on the connectivity
of a network. A higher connectivity suggests a higher network efficiency. The network
efficiency is defined by
η =
1
n(n− 1)
∑
vi 6=vj∈V
1
dij
, (4.9)
where n is the total number of vertices in the network, V is the vertex set, and dij is
the distance, i.e., shortest path length, between vertex vi and vj. Thus, the decline
rate of the network efficiency is calculated as
µ = 1− η
η0
, (4.10)
where η0 is the efficiency of the original network, and η is the network efficiency after
some vertices are removed.
When a more important vertex is removed, we expect to see a greater decline rate
of the network efficiency. Thus we can use µ as a indicator for the actual impact of
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Figure 4.3: Correlation of DIL-W scores with a) degree centrality, b) closeness centrality,
and c) betweenness centrality in the WHDN.
removing a vertex in the network. Figure 4.4 shows the decline rate of the network
efficiency when we remove each of the top 40 vertices ranked by a) degree (DC), b)
closeness (CC), c) betweenness (BC), and d) DIL-W. Further removal of top ranked
vertices could be investigated but was not included in the current study given the
high computational demand.
35
0 5 10 15 20 25 30 35 40
Rank (DC)
0.0000
0.0005
0.0010
0.0015
0.0020
0.0025
0.0030
D
e
cl
in
e
 r
a
te
 o
f 
n
e
tw
o
rk
 e
ff
ic
ie
n
cy
ρ=-0.1801
p-value=0.2661
(a)
0 5 10 15 20 25 30 35 40
Rank (CC)
0.0000
0.0005
0.0010
0.0015
0.0020
0.0025
0.0030
D
e
cl
in
e
 r
a
te
 o
f 
n
e
tw
o
rk
 e
ff
ic
ie
n
cy
ρ=-0.0017
p-value=0.9917
(b)
0 5 10 15 20 25 30 35 40
Rank (BC)
0.0000
0.0005
0.0010
0.0015
0.0020
0.0025
0.0030
D
e
cl
in
e
 r
a
te
 o
f 
n
e
tw
o
rk
 e
ff
ic
ie
n
cy
ρ=-0.0679
p-value=0.6771
(c)
0 5 10 15 20 25 30 35 40
Rank (DIL-W)
0.0000
0.0005
0.0010
0.0015
0.0020
0.0025
0.0030
D
e
cl
in
e
 r
a
te
 o
f 
n
e
tw
o
rk
 e
ff
ic
ie
n
cy
ρ=-0.2698
p-value=0.0923
(d)
Figure 4.4: Decline rate of network efficiency after removing a single vertex ranked by a)
degree centrality (DC), b) closeness centrality (CC), c) betweenness centrality (BC), and
d) DIL-W.
As shown in the Figure 4.4, we do not observe a monotonic relationship across all
four centrality methods. However, the correlation analysis shows that our method,
DIL-W, has a slightly stronger negative correlation between the decline rate and the
rank of the removed vertex than the other three. The Spearman’s rank correlation
coefficient for degree, closeness, and betweenness is −0.18, −0.001, and −0.06, re-
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Figure 4.5: The decline rate of the network efficiency as a function of removing the top m
vertices ranked by degree centrality (DC), closeness centrality (CC), betweenness centrality
(BC), and DIL-W.
spectively. In comparison, DIL-W has a negative correlation coefficient −0.26.
We also consider removing all m top-rank vertices at once to see how this accumu-
lative removal affects the efficiency of the network. Figure 4.5 shows the decline rate
of the network efficiency after removing top m vertices ranked by different central-
ity measures. The graph shows that the proposed method, DIL-W, has the highest
decline rate of network efficiency for 57.5% of the data points, while betweenness,
closeness, and degree have 27.5%, 10%, and 5%, respectively. This suggests that
DIL-W is able to select a set of more important vertices comparing with the other
three centrality measures. As seen in Figure 4.5 , the four methods are very com-
petitive until the top 11 diseases are removed from the network. Then DIL-W has a
significant higher network efficiency decline rate than the rest. Betweenness centrality
37
catches up at point 31 and becomes very competitive afterwards.
We take a closer look at the top 31 diseases ranked by DIL-W since this is the
most important set of diseases that resulted from the comparative study. Table 4.1
shows the top 31 diseases ranked by each centrality measure. Diseases that appear
in multiple columns are shown with colors.
Table 4.1: Top 31 vertices in the WHDN ranked by different centrality measurements.
RankDIL-W CC DC BC
1 Epilepsy Epilepsy Epilepsy Epilepsy
2 Pediatric failure
to thrive
Pediatric failure
to thrive
Pediatric failure
to thrive
Pediatric failure
to thrive
3 Sensorineural
hearing loss
Nystagmus Nystagmus Nystagmus
4 Anemia Strabismus Sensorineural
Hearing loss
Obesity
5 Obesity Sensorineural
hearing loss
Strabismus Anemia
6 Osteoporosis Optic atrophy Obesity Sensorineural
hearing loss
7 Nystagmus Retinitis pigmen-
tosa
Optic atrophy Heart failure
8 Liver cirrhosis Cerebral atrophy Retinitis pigmen-
tosa
Strabismus
9 Low vision Obesity Cerebral atrophy Osteoporosis
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Table 4.1: Top 31 vertices in the WHDN ranked by different centrality measurements.
RankDIL-W CC DC BC
10 Heart failure Low vision Low vision Chemical and
drug induced
liver injury
11 Muscle degenera-
tion
Hypogonadism Heart failure Muscle degenera-
tion
12 Diabetes melli-
tus, non-insulin-
dependent
Developmental
regression
Osteoporosis Retinitis pigmen-
tosa
13 Strabismus Glaucoma Anemia Liver cirrhosis
14 Exophthalmos Blindness, legal Diabetes melli-
tus, non-insulin-
dependent
Endometriosis
15 Myopia Conductive hear-
ing loss
Muscle degenera-
tion
Rheumatoid
arthritis
16 Degenerative
polyarthritis
Supratentorial
atrophy
Chemical and
drug induced
liver injury
Diabetes melli-
tus, non-insulin-
dependent
17 Cerebral atrophy Hyperinsulinism Hypogonadism Hypertrophic
cardiomyopathy
18 Optic atrophy Night blindness Liver cirrhosis Low vision
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Table 4.1: Top 31 vertices in the WHDN ranked by different centrality measurements.
RankDIL-W CC DC BC
19 Rheumatoid
arthritis
Dystonic disease Conductive hear-
ing loss
Myocardial
infarction
20 Hydrocephalus Atrophy of cere-
bellum
Anxiety disease Hydrocephalus
21 Alopecia Cerebellar de-
generation
Rheumatoid
arthritis
Degenerative
polyarthritis
22 Myocardial
ischemia
Infratentorial at-
rophy
Glaucoma Amyotrophic lat-
eral sclerosis
23 Myocardial
infarction
Hypoglycemia Myopia Neonatal hypoto-
nia
24 Chemical and
drug induced
liver injury
Keratoconus Blindness Exophthalmos
25 Asthma Gastroesophageal
reflux disease
Developmental
regression
Myocardial
ischemia
26 Endometriosis Heart failure Hydrocephalus Myopia
27 Hypertrophic
cardiomyopathy
Hydrocephalus Dystonic disease Optic atrophy
28 Conductive hear-
ing loss
Anemia Atrophy of cere-
bellum
Coronary artery
disease
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Table 4.1: Top 31 vertices in the WHDN ranked by different centrality measurements.
RankDIL-W CC DC BC
29 Brain ischemia Neonatal hypoto-
nia
Cerebellar de-
generation
Glaucoma
30 Gastroesophageal
reflux disease
Muscle degenera-
tion
Infratentorial at-
rophy
Alzheimer’s dis-
ease
31 Anxiety disease Spastic
quadriplegia
Myocardial
ischemia
Polycystic ovary
syndrome
Diseases that appear in multiple columns are shown with colors.
4.2 Measuring Vertex Importance in WGN
4.2.1 A special case in the DIL-W Method
We extend the DIL-W method proposed in the previous section to rank the vertices
in the WGN. Although the DIL-W method provides a better result in terms of finding
the most central vertices, there is a special case in which the DIL-W cannot distinguish
between two links. The DIL-W does not take into account the number of triangles, t,
into calculating the link importance. Recall Equation 4.1 which is used to calculate
the link importance. In this equation, the Ueij can be calculated by:
Ueij = (si − pi)(sj − pj) and λeij = pi+pj2 + 1
where si is the strength of vertex vi, calculated by Formula (3.5), and pi is the sum
of link weights incident to vertex vi that form triangles with eij.
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As shown in the equation above, only pi can contribute to calculate the link
importance, while the number of triangles t should be considered as well.
In a situation where the values of si, sj, pi, and pj are the same for two different
links, while the number of triangles is different, the final value of link importance will
be the same. In such a case, the number of triangles can make a difference between
the values of link importance.
An example can be illustrated by looking at Figure 4.6 where both links eab in
network (a) and eAB in network (b) have the same value 10.1538 where their link
importance can be calculated as follows:
Ieab =
Ueab
λeab
For network (a) we have
sa = 12 , pa = 6, sb = 16 , pb = 5
So
Ieab =
((12−6)∗(16−5))
11
2
+1
= 10.1538
There are similar values for the parameters in the network (b).
sA = 12 , pA = 6, sB = 16 , pB = 5
Then
IeAB = 10.1538
By considering the number of triangles, we can distinguish between the links of the
same importance. In the given example, link eab consists of two triangles with vertices
c and d, while link eAB can only make a triangle with vertex C.
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Figure 4.6: Two example networks.
4.2.2 Opsahl Method
The common methods for calculating degree centrality (DC) in unweighted and
weighted networks is counting the number of links of vertex i and the strength,
i.e., the total sum of the weights of links connected to vertex i, respectively. The
number of links is neglected in computing DC in weighted networks and only the link
weights contribute to DC. The main purpose of the Opsahl’s [1] method is to consider
both vertex degree and link weights together while calculating vertex importance. As
shown in Figure 4.7, the strength of vertices A and B are the same. In this network,
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Figure 4.7: A network with 6 vertices and 6 weighted links. The size of links correspond
to the link weights [1].
vertex A has two links while there are four links for vertex B. Since the number of
links does not contribute to vertex strength, both A and B have the same score.
To distinguish between vertices A and B, a tuning parameter α is used to balance
the number of links and the link weights. The formula for calculating degree centrality
is as follows:
CwαD (i) = ki × (
si
ki
)α = k
(1−α)
i × sαi (4.11)
where α is a positive parameter and si is the sum of link weights which can be
calculated by Equation 3.5, and ki is the number of links connected to vertex i:
ki =
N∑
j
xij (4.12)
where x is an adjacency matrix in which xij is 1 if there is a link between vertex i
and vertex j, and 0 otherwise.
Table 4.2 shows the effect of α on the value of degree centrality. When α is between
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Table 4.2: Degree centrality of vertices with different values of α
Vertex ki si C
wα=0
D C
wα=0.5
D C
wα=1
D C
wα=1.5
D
A 2 8 2 4 8 16
B 4 8 4 5.7 8 11.3
C 2 6 2 3.5 6 10.4
D 1 1 1 1 1 1
E 2 8 2 4 8 16
F 1 7 1 2.6 7 18.5
0 and 1, the higher degree causes a higher score. For example, in the case of α = 0.5,
B has a higher score than A because vertex B has a higher degree. When α is greater
than 1, the fewer number of vertex degree is favorable. For instance, when α = 1.5,
vertex A has a higher score compared with vertex B. CwαD is equal to ki when α is 0.
It means the CwαD score is equal to the vertex degree. C
wα
D is equal to si when α is 1.
That is, the CwαD score is equal to the total sum of link weights.
By applying tuning parameter α, the closeness centrality can be defined as follows:
CwαC (i) =
[
N∑
j
dwα(i, j)
]−1
(4.13)
where the shortest distance between vertices i and j can be calculated as follows:
dwα(i, j) = min(
1
(wih)α
+ ...+
1
(whj)α
) (4.14)
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Finally, the betweenness centrality is defined as follows:
CwαB (i) =
gwαjk (i)
gwαjk
(4.15)
where gwαjk (i) is the number of intermediary vertices and g
wα
jk refers to the link weights.
4.2.3 Proposed Method (EDIL-W)
The proposed method is called EDIL-W, which is an extension of the DIL-W method
discussed in Section 4.1.1. There is a crucial question about the role of the number of
triangles, t, and the sum of link weights, pi, incident to vertex vi that form triangles
with eij. One can view the number of triangles as more important than pi. That is,
the presence of many triangles with any pi might be considered more significant than
pi. On the other hand, pi can be considered as a more important factor compared with
the number of triangles in a weighted network. This trade-off is the most important
reason for extending the DIL-W method where EDIL-W takes into account both the
number of triangles, t, and pi in calculating link importance.
The EDIL-W is defined as follows:
Iαeij =
UEeij
λEeij
, (4.16)
We modify the computation of U in Equation (4.4) as
UEeij = (C
wα
i − Pwαi )× (Cwαj − Pwαj ) (4.17)
where Cwαi is the measure to compute centrality of vertex vi, calculated by Formula
(4.11), and Pwαi can be defined as follows:
Pwαi = t
(1−α) × pαi (4.18)
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where t refers to the number of triangles that include link eij as one of three edges,
and pi is the sum of link weights incident to vertex vi that forms triangles with eij.
From Equation 4.17, we know that, first, the importance of a link, eij, is dependent
on both degrees of two end vertices, vi and vj, and their link weights in the case of
calculating the strength of vertices Cwαi and C
wα
j . When α is between 0 and 1, high
degree is favorable. When α is greater than 1, low degree is favorable and link weights
contribute more to calculate the strength of vertices. Second, the importance of the
link, eij, is reduced when there is an alternative two-hop path that connects the same
set of end vertices (Pwαi and P
wα
j ). In this case, both the number of triangles, t,
and the sum of link weights, pi, connecting the same set of end vertices contribute to
reducing the link importance. When α is between 0 and 1, a fewer number of triangles
is favorable. When α is greater than 1, a greater number of triangles increases link
importance and pi contribute more to link importance. A link is considered more
important when its two end vertices have a higher centrality score Cwαi and a lower
Pwαi . Therefore, we subtract P
wα
i from C
wα
i in Equation (4.17).
We define λ for EDIL-W as
λEeij =
Pwαi + P
wα
j
2
+ 1. (4.19)
Finally, the importance of a vertex can be measured by
EDIL-Wvi = C
wα
i +
∑
vj∈Γi
Cvivj , (4.20)
where Cvivj is defined as
Cvivj = I
α
eij
× C
wα
i
Cwαi i+ C
wα
j
. (4.21)
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For example, in Figure 4.6, the importance of links eab in the network (a) and eAB in
the network (b) is the same if the DIL-W method proposed in the previous section is
applied. By applying EDIL-W on network (a), we will have
when α = 0.5
for the network (a)
Cwαa = 4
0.5 × 120.5 = 6.9282, Cwαb = 50.5 × 160.5 = 8.9442,
Pwαa = 2
0.5 × 60.5 = 3.4641, and Pwαb = 10.5 × 50.5 = 3.1622
then
I0.5eab =
(6.9282−3.4641)×(8.9442−3.1622)
3.4641+3.1622
2
+1
= 4.6438
For the network (b) we have
CwαA = 6.9282, C
wα
B = 8.9442, P
wα
A = 2.4494, and P
wα
B = 2.2360
then
I0.5eAB = 8.9881
When α = 1.5, for the network (a), we have
Cwαa = 4
−0.5 × 121.5 = 20.7846, Cwαb = 5−0.5 × 161.5 = 28.6216,
Pwαa = 2
−0.5 × 61.5 = 10.3923, and Pwαb = 1−0.5 × 51.5 = 7.9056
then
I1.5eab =
(20.7846−10.3923)×(28.6216−7.9056)
10.3923+7.9056
2
+1
= 21.2127
For the network (b) we have
CwαA = 20.7846, C
wα
B = 28.6216, P
wα
A = 14.6969, and P
wα
B = 11.1803
then
I1.5eAB = 7.6175
Since all parameters including vertex strength, the number of links, and the value
of parameter pi are the same for both links eab and eAB, we cannot distinguish between
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these two links by applying the DIL-W method. The EDIL-W method can easily
solve this issue by adding a tuning parameter α. This parameter can create a balance
between the number of triangles, t, and pi.
When α = 0.5, a smaller number of triangles is favorable. That is, less triangles
increases the link importance score. For example, in Figure 4.6, link eab in the network
(a) creates two triangles. Therefore, the amount of Pwαa will be increased when
α = 0.5, which results in a decreased link importance score. That is the reason that
link eAB seems more important than eab. The results are different by setting α to
1.5. In this case, a larger number of triangles is favorable. As result shown, the link
importance score for eab is higher than eAB, which means link eAB is more important.
Table 4.3 shows the importance of all links of Figure 4.6 obtained by the EDIL-W
method. The scores change when changing the value of α. For example, both links eac
and eAC have the same importance value when α = 1. As shown in Figure 4.6, both
links create one triangle, where pC is greater than pc and sC is greater than sc. The
difference between these two parameters changes the link importance by changing the
α value. When α = 0.5, eAC is more important than eac, and when α = 1.5, the link
eac is more important than eAC .
In the case of an absence of triangles, there is still a possibility of having the same
score for different links when α = 1. For example, eae and eBH have the same score
since there is no triangle and the result of equation 4.17 for both links is the same.
EDIL-W can distinguish between links in such a situation. When α is between 0 and
1, the higher number of links is favorable.
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Table 4.3: The importance of links in the networks of figure 4.6 obtained by EDIL-W.
Link Iα=0.5eij I
α=1
eij
Iα=1.5eij
bf 15.4919 48.0 148.7225
cb 4.0725 7.0 9.62
bg 21.9089 96.0 420.650
ae 13.8564 48.0 166.2768
ad 3.0648 5.7142 9.7067
ab 4.6438 10.1538 21.2127
ac 4.6818 13.3333 35.4762
bd 5.45230 14.0 34.2070
AF 9.7979 24.0 58.7877
BH 15.4919 48.0 148.7225
CB 5.7555 14.0 29.3273
BG 12.6491 32.0 80.9543
AE 9.7979 24.0 58.78775
AB 8.9881 10.1538 7.6175
AC 4.7902 13.3333 32.7901
BD 17.8885 64.0 228.9733
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Figure 4.8: Distribution of EDIL-W centrality in the giant component of the WGN on a
log-log scale with a) α = 0.5, b) α = 1, and c) α = 1.5
When alpha is greater than 1 the less number of links is favorable. When α = 0.5,
eBH is more important than eae because the degree of vertex B (kB = 5) is more than
degree of vertex a (ka = 4). As a result, link eBH is more important than eae. When
α = 1.5, link eae is more important than eBH .
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4.2.4 Results
We apply the EDIL-W measurement to the giant component of the backbone of WGN,
the distribution is shown in Figure 4.8. The EDIL-W scores, with α = 0.5 have a high
dynamic range from 0.1180 to 81220.2734. By setting α to 1 and 1.5, the dynamic
ranges are from 0.0115 to 29743.2460 and from 0.0012 to 10254.1827, respectively.
The majority of vertices in each case with different α values have low scores and a
few number of vertices have scores that are greater by orders of magnitude.
For the next step, we compare our newly extended method, EDIL-W, with three
of the most commonly used centralities, i.e., degree, closeness, and betweenness, when
applied to the giant component of the WGN. We use a generalized form of DC, CC,
and BC proposed by [1] which can be calculated by Equations 4.11, 4.13, and 4.15,
respectively.
We set the tuning parameter α to three different values 0.5, 1, and 1.5. Figure 4.9
to 4.11 show the correlation of EDIL-W with three other measures. As we can see
there is a positive correlation between the EDIL-W measure and the other measures.
When α = 0.5, the Spearman’s rank correlation coefficient is 0.95 comparing EDIL-W
with degree centrality, 0.67 comparing EDIL-W with closeness centrality, and 0.82
comparing EDIL-W with betweenness centrality. When α = 1, the Spearman’s rank
correlation coefficient is 0.97, 0.77, and 0.78 comparing EDIL-W with degree, close-
ness, and betweenness centralities. Finally, the Spearman’s rank correlation coefficient
is 0.97, 0.85, and 0.75 comparing EDIL-W with degree, closeness, and betweenness
centralities when α = 1.5.
To evaluate our new vertex importance qualification method, EDIL-W, we calcu-
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Figure 4.9: Correlation of EDIL-W scores with a) degree centrality, b) closeness centrality,
and c) betweenness centrality when α = 0.5 in the WGN.
late the decline rate of network efficiency after removing top m vertices selected by
different measures to see how this accumulative removal affects the efficiency of the
network. Figure 4.12 shows the decline rate of the network efficiency after removing
top m vertices ranked by different measures.
When α = 0.5, the fewer number of triangles is favorable. As we can see in
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Figure 4.10: Correlation of EDIL-W scores with a) degree centrality, b) closeness centrality,
and c) betweenness centrality when α = 1 in the WGN.
Figure 4.12a, the new proposed method, EDIL-W, performs better than the degree
and closeness centralities, but it is less effective than betweenness centrality. When
α = 1, the method will be the same as the DIL-W method proposed in Section
4.1.1. In this case, EDIL-W still performs better compared with degree and closeness
centralities. Based on the decline rate of network efficiency given in Figure 4.12b, it
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Figure 4.11: Correlation of EDIL-W scores with a) degree centrality, b) closeness centrality,
and c) betweenness centrality when α = 1.5 in the WGN.
seems that the top 12 vertices ranked by EDIL-W are more important than the top 12
vertices selected by betweenness centrality, which means that there may be stronger
interactions among corresponding genes selected by EDIL-W than those selected by
betweenness centrality in the network. Finally, Figure 4.12c, when α = 1.5, indicates
our proposed method outperforms other three centrality measures to find the most
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Figure 4.12: The decline rate of the network efficiency as a function of removing the top m
vertices ranked by applying different values of a) α = 0.5 b) α = 1, and c) α = 1.5 on degree
centrality (DC), closeness centrality (CC), betweenness centrality (BC), and EDIL-W.
important top 23 vertices. That is, the top 23 genes selected by the EDIL-W method
may have strong interaction with each other. In conclusion, the new proposed method
under any value of alpha, identifies more important vertices compared with degree
and closeness centralities. In comparison with betweenness centrality, the EDIL-W
works less effectively when α is 0.5, but is more effective at finding some top vertices
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Table 4.4: Top 12 genes in the WGN ranked by different centrality measurements when
α = 1.
Rank DC CC BC EDIL-W
1 LMNA LMNA LMNA LMNA
2 TNF TNF TNF TNF
3 FGFR2 ZMPSTE24 FGFR2 GBA
4 BRAF IL1B FGFR3 BRAF
5 ELN IL6 PIK3CA PTEN
6 FGFR1 MMP9 PTEN FGFR2
7 IL1B WRN SOD1 POMC
8 ERCC6 TGFB1 IL1B ALMS1
9 PTEN HGD FAS ERCC6
10 IL6 IL10 FBN1 POLG
11 FBN1 LBR GJB2 INS
12 FGFR3 GJB2 LDLR GNAS
Diseases that appear in multiple columns are shown with colors.
when α is 1 and at finding more important vertices when α is 1.5.
The point is that both closeness and betweenness centralities are based on the
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shortest distance among vertices, which are not applicable measures to identify the
most important vertices in a network with disconnected components. Betweenness
centrality has another disadvantage where some vertices do not lie on the shortest
paths between a pair of vertices. In such a case, betweenness centrality gives the
vertices a value of zero. For example, the betweenness centrality gives positive value
to only about 45 percent of the vertices in the gene network when α is 0. This is
40 and 35 percent when α value is 1 and 1.5, respectively. Therefore, the EDIL-W
method outperforms the other three measures in finding the most important vertices.
Tables 4.4 and 4.5 show the top 12 and 23 most important genes selected by
EDIL-W when α is 1 and 1.5, respectively. Genes that appear in multiple columns
are shown with colors.
Table 4.5: Top 23 genes in the WGN ranked by different centrality measurements when
α = 1.5.
Rank DC CC BC EDIL-W
1 LMNA TNF TNF LMNA
2 TNF LMNA LMNA TNF
3 FGFR2 IL6 FGFR2 GBA
4 FAS IL1B NOS2 FGFR2
5 FBN1 ZMPSTE24 IL6 PTEN
6 IL1B MMP9 FBN1 BRAF
7 ELN WRN PIK3CA POMC
8 FGFR1 IL1A SOD1 TBX1
9 TGFB1 IL10 FGFR3 FGFR1
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Table 4.5: Top 23 genes in the WGN ranked by different centrality measurements when
α = 1.5.
Rank DC CC BC EDIL-W
10 PTEN NOS2 MMP9 APOE
11 FGFR3 HGD PTEN FBN1
12 APOE TGFB1 GJB2 POLG
13 SCN5A IFNG FAS ALMS1
14 BRAF LBR SCN9A ELN
15 COL2A1 GJB2 LDLR ERCC6
16 IL6 PPARG IL1B TGFB1
17 GBA BSCL2 SCN10A FLNA
18 HBB AGPAT2 CYP19A1 GNAS
19 HLA-DRB1 HLA-DRB1 FGFR1 COL2A1
20 TRNL1 GJB6 HLA-DRB1 IL6
21 ZMPSTE24 LDLR IFNG FGFR3
22 SOD1 CSF3 IL10 INS
23 COL1A1 ALB FLNA IL1B
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Chapter 5
Discussion
In this project, we use a network-based analysis to identify important human dis-
eases that share a genetic background with many other diseases through strong as-
sociations. In addition, we identify important disease genes associated with different
diseases. We collect a large number of known disease-gene associations (DGAs) using
the DisGeNET database in order to construct a bipartite disease-gene network. Sub-
sequently, a weighted human disease network (WHDN) is built by connecting pairs
of diseases that share associated genes. The edge weights reflect the number of genes
they share as well as the strength of the DGAs. In a similar way, we construct a
weighted gene network (WGN) in which link weights show the strength of interac-
tions between gene pairs. Then, two methods are proposed to rank the vertices based
on their centralities in the networks. To evaluate the proposed methods, results are
compared with three commonly used centrality measures.
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5.1 The Most Important Diseases
To identify the most important diseases, we propose a new vertex centrality measure,
DIL-W, that considers both the degree of a vertex and the importance of its incident
edges in weighted graphs. Upon application to the WHDN, DIL-W is shown to
outperform degree, closeness and betweenness to find the important diseases. The
DIL-W method is able to identify a set of 31 important diseases including epilepsy,
anemia, and obesity.
As shown in Table 4.1, all four methods rank epilepsy and pediatric failure to
thrive as the two most important diseases in the network. Sensorineural hearing loss
is found as the third important disease by DIL-W whereas all other methods pick
nystagmus. As we can see in Figure 4.4 d), sensorineural hearing loss (rank 3) has a
higher decline rate of network efficiency than nystagmus (rank 7).
We show a visualization of the subnetwork including the top 31 diseases ranked by
DIL-W in Figure 5.1. The 31 top-rank diseases not only appear very central on the
entire WHDN but also have a large number of interconnections among themselves.
They may be regarded as a dense core of the WHDN. In addition, epilepsy, pediatric
failure to thrive, obesity, heart failure, and osteoporosis correlate with many other
diseases in this subgraph, reflected by their vertex size. Some neurological diseases
also tend to form a cluster.
Table 5.1 shows the degree in the WHDN and the most correlated disease of those
31 top-rank diseases. We are also able to find previous publications that verify al-
most all the correlations of the pairs of diseases, which are referenced in the table.
Besides some very well-known correlations such as heart failure - obesity and diabetes
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cerebral atrophy
exophthalmos
pediatric failure to thrive
epilepsyoptic atrophy
nystagmus
sensorineural hearing loss 
(disorder) 
liver cirrhosis
osteoporosis
myocardial ischemia
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chemical and drug induced 
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disease anemia
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hypertrophic cardiomyopathy
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strabismus
low vision
Figure 5.1: Subgraph of the WHDN that includes the 31 top diseases ranked by DIL-W.
The size of a vertex is proportional to its degree. The width of an edge is proportional
to its weight. Thicker edges indicate stronger disease correlations based on our weighting
method defined in section 3.3. The gray scale of the edges is also proportional to their
weights for visualization purposes. The network is shown using a force-directed layout such
that vertices with stronger links appear closer.
- obesity, the table also reports some less known but interesting correlations. For
instance, Savin [86] showed that atypical retinitis pigmentosa is correlated with obe-
sity. Moreover, the correlation between anemia and pediatric failure to thrive had not
been reported in the literature until recently Dimmock et al. [87] suggested anemia
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as one of the novel causes of failure to thrive in children. Zimmerman [88] studied
the cause of different types of cirrhosis resulting from different drug-induced injuries.
This supports our finding on the correlation between cirrhosis and chemical and drug
induced liver injury.
Table 5.1: The diseases that have the most correlation with top 31 ranked diseases.
Rank Disease Degree The most correlated
disease
Reference
1 Epilepsy 576 Pediatric failure to
thrive
–
2 Pediatric failure to
thrive
462 Epilepsy –
3 Sensorineural hearing
loss (disorder)
313 Retinitis pigmentosa [89]
4 Anemia 327 Pediatric failure to
thrive
[87]
5 Obesity 268 Retinitis Pigmentosa [86]
6 Osteoporosis 326 Osteopenia [90]
7 Nystagmus 276 Epilepsy [91]
8 Liver cirrhosis 278 Chemical and drug in-
duced liver injury
[88]
9 Low vision 270 Nystagmus [92]
10 Heart failure 311 Obesity [93]
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Table 5.1: The diseases that have the most correlation with top 31 ranked diseases.
Rank Disease Degree The most correlated
disease
Reference
11 Muscle degeneration 277 Amyotrophic lateral
sclerosis
[94]
12 Diabetes mellitus,
non-insulin-dependent
245 Obesity [95]
13 Strabismus 293 Epilepsy [96]
14 Exophthalmos 302 Strabismus [97]
15 Myopia 266 Sensorineural hearing
loss (disorder)
[98]
16 Degenerative pol-
yarthritis
239 Rheumatoid arthritis [99]
17 Cerebral atrophy 267 Epilepsy [100]
18 Optic atrophy 236 Nystagmus –
19 Rheumatoid arthritis 188 Lupus erythematosus,
systemic
[101]
20 Hydrocephalus 250 Epilepsy [102]
21 Alopecia 241 Dystrophia unguium –
22 Myocardial ischemia 166 Obesity –
23 Myocardial infarction 228 Coronary artery dis-
ease
[103]
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Table 5.1: The diseases that have the most correlation with top 31 ranked diseases.
Rank Disease Degree The most correlated
disease
Reference
24 Chemical and drug in-
duced liver injury
174 Cholestasis [104]
25 Asthma 198 Dermatitis, atopic [105]
26 Endometriosis 135 Obesity [106]
27 Hypertrophic car-
diomyopathy
187 Pediatric failure to
thrive
[107]
28 Conductive hearing
loss
163 Sensorineural hearing
loss (disorder)
[108]
29 Brain ischemia 191 Diabetes mellitus,
non-insulin-dependent
–
30 Gastroesophageal re-
flux disease
190 Epilepsy [109]
31 Anxiety disease 185 Amyotrophic Lateral
Sclerosis
[110]
5.2 The Most Important Genes
To identify the important disease-associated genes in the WGN, we extend the pro-
posed method, DIL-W, to the method called EDIL-W. The purpose of this extension
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is to consider both the number of triangles and the sum of link weights incident to
vertex vi, which form a triangle with eij when calculating link importance. Recall
that vi is one of the end vertices of link eij. In addition, we balance the number
of links and link weights when calculating vertex strength by adding a tuning pa-
rameter α. Table 4.4 shows the top 12 genes in WGN ranked by different centrality
measures when α = 1. LMNA and TNF are the first and second most central genes
in the WGN, respectively, which are introduced by all centrality measures. Close-
ness centrality and then EDIL-W methods have the highest number of unique genes
among all four methods. From Figure 4.12b, closeness centrality performs the least
effectively among all four methods, while EDIL-W outperforms other three centrality
measures in terms of finding the most important genes. Identifying the genes as the
more important ones, which can not be found by other measures, can be considered
as an important aspect of the proposed measure.
Table 5.2 shows the top 12 genes selected by EDIL-W when α = 1. This table
shows the degree of selected genes in the WGN and the genes that have the strongest
interaction with them. In addition, the disease that has the strongest association
with the corresponding gene is shown in the table.
We show a visualization of the subnetwork including the top 12 genes ranked by
EDIL-W in Figure 5.2. This figure shows the interconnection among the top 12 genes,
not the other genes connected to them. ALMS1 and LMNA have the highest degree in
the subgraph. From Table 5.2, we know the disease that is directly connected to the
subgraph through one of the genes. Other genes in the subgraph that are not directly
connected to the disease can be considered as candidate genes. Candidate genes are
the genes that probably have an association with the diseases, but we are not sure
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INS TNF
ERCC6
LMNA
GNAS
POLG
GBA
PTEN
FGFR2
ALMS1
POMC
BRAF
Figure 5.2: Subgraph of the WGN that includes the 12 top genes ranked by EDIL-W
when α = 1. The size of a vertex is proportional to its degree. The width of an edge is
proportional to its weight. Thicker edges indicate stronger gene interactions based on our
weighting method defined in section 3.4. The gray scale of the edges is also proportional to
their weights for visualization purposes. The network is shown using a force-directed layout
such that vertices with stronger links appear closer.
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about that. For example, disease progeria is connected to subgraph through gene
LMNA. Gene LMNA has 10 links in the subgraph, where its strongest interaction is
with ZMPSTE24 according to Table 5.2, which is not part of the subgraph. Then,
all other 11 genes can be considered as potential candidate genes if no association
has been already recognized between disease progeria and these 11 genes from the
dataset.
Table 5.2: The genes that have the strongest interaction as well as the diseases that have
the strongest association with top 12 ranked genes selected by EDIL-W when α = 1.
Rank Gene Degree The most in-
teracted gene
The most associated disease
1 LMNA 449 ZMPSTE24 progeria
2 TNF 429 IL1B rheumatoid arthritis
3 GBA 369 SCARB2 gaucher disease, type 1
4 BRAF 463 PTPN11 noonan syndrome
5 PTEN 299 AKT1 macrocephaly/autism syndrome
6 FGFR2 338 FGFR3 cutis gyrata syndrome of beare and
stevenson
7 POMC 296 COL2A1 obesity
8 ALMS1391 DICER1 alstrom syndrome
9 ERCC6532 ERCC8 cockayne syndrome, type ii
10 POLG 412 TYMP alpers syndrome (disorder)
11 INS 384 KCNJ11 diabetes mellitus, permanent neonatal
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Table 5.2: The genes that have the strongest interaction as well as the diseases that have
the strongest association with top 12 ranked genes selected by EDIL-W when α = 1.
Rank Gene Degree The most in-
teracted gene
The most associated disease
12 GNAS 397 STX16 pseudohypoparathyroidism, type Ia
To evaluate the importance of the genes selected by the EDIL-W, we use DAVID
[111, 112] (Database for Annotation, Visualization and Integrated Discovery) appli-
cation v.6.8 to extract biological meanings from top 12 genes selected by EDIL-W.
Table 5.3 shows a functional annotation chart of the 12 gene list. In this chart,
‘Category’ refers to original databased/resources where the terms orient, ‘Term’ lists
enriched terms associated with the top 12 genes, ‘Genes’ refers to those genes involved
in the term, and ‘p-value’ shows the Modified Fisher Exact p-value, Ease Score. The
nineteen most significant terms based on p-value out of 35 are shown in this table
which are sorted by p-value.
Table 5.3: Functional annotation chart of top 12 ranked genes selected by EDIL-W with
α = 1
Category Term Genes p-value
KEGG-PATHWAY prostate cancer FGFR2, INS, PTEN,
BRAF
3.7E-4
69
Table 5.3: Functional annotation chart of top 12 ranked genes selected by EDIL-W with
α = 1
Category Term Genes p-value
GOTERM-BP-
FAT
positive regulation of de-
velopmental process
GNAS, FGFR2, TNF 3.3E-3
SP-PIR-
KEYWORDS
cleavage on pair of basic
residues
GNAS, INS, POMC 3.7E-3
KEGG-PATHWAY dilated cardiomyopathy GNAS, LMNA, TNF 8.0E-3
GOTERM-BP-
FAT
regulation of osteoclast
differentiation
GNAS, TNF 8.7E-3
UP-SEQ-
FEATURE
disulfide bond GBA, INS, POMC,
TNF
8.9E-3
SP-PIR-
KEYWORDS
myristylation GNAS, TNF 1.2E-2
GOTERM-BP-
FAT
regulation of myeloid
leukocyte differentiation
GNAS, TNF 1.5E-2
GOTERM-BP-
FAT
regulation of cell prolifer-
ation
FGFR2, PTEN, TNF 1.8E-2
SP-PIR-
KEYWORDS
disulfide bond GBA, INS, POMC,
TNF
2.0E-2
GOTERM-BP-
FAT
regulation of myeloid cell
differentiation
GNAS, TNF 2.5E-2
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Table 5.3: Functional annotation chart of top 12 ranked genes selected by EDIL-W with
α = 1
Category Term Genes p-value
GOTERM-BP-
FAT
embryonic organ mor-
phogenesis
GNAS, FGFR2, 3.7E-2
SP-PIR-
KEYWORDS
glycoprotein GNAS, GBA, POMC,
TNF
4.1E-2
GOTERM-BP-
FAT
bone development GNAS, FGFR2 4.2E-2
GOTERM-BP-
FAT
ossification GNAS, FGFR2 4.2E-2
KEGG-PATHWAY regulation of actin cy-
toskeleton
FGFR2, INS, BRAF, 4.4E-2
GOTERM-BP-
FAT
embryonic organ devel-
opment
GNAS, FGFR2 4.8E-2
GOTERM-BP-
FAT
egulation of cell adhesion PTEN, TNF 4.9E-2
SP-PIR-
KEYWORDS
hormone INS, POMC 5.0E-2
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Figure 5.3: Subgraph of the WGN that includes the 23 top genes ranked by EDIL-W
when α = 1.5. The size of a vertex is proportional to its degree. The width of an edge is
proportional to its weight. Thicker edges indicate stronger gene interactions based on our
weighting method defined in section 3.4. The gray scale of the edges is also proportional to
their weights for visualization purposes. The network is shown using a force-directed layout
such that vertices with stronger links appear closer.
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Table 4.5 shows the 23 important significant genes extracted by EDIL-W when
α = 1.5. Here, EDIL-W select the highest number of unique genes after the closeness
centrality. Unique genes refer to those genes which cannot be selected by other cen-
trality measures. Since results show that the closeness centrality is the least effective
among the four methods, EDIL-W can be considered as the method with the most
unique results.
We show a visualization of the subnetwork including the top 23 genes ranked by
EDIL-W in Figure 5.3. This figure shows the interconnection among the top 23 genes,
excluding other genes connected to them. ALMS1, LMNA, and ELN have the highest
degree in the subgraph.
Table 5.4 shows the top 23 genes selected by EDIL-W when α = 1.5. This table
shows the degree of genes in the WGN and the most interacted gene and the most
associated disease with the corresponding gene.
Table 5.4: The genes that have the strongest interaction as well as the diseases that have
the strongest association with top 23 ranked genes selected by EDIL-W when α = 1.5
Rank Gene Degree The most in-
teracted gene
The most associated disease
1 LMNA 449 ZMPSTE24 progeria
2 TNF 429 IL1B rheumatoid arthritis
3 GBA 369 SCARB2 gaucher disease, type 1
4 FGFR2 338 FGFR3 cutis gyrata syndrome of beare and
stevenson
5 PTEN 299 AKT1 macrocephaly/autism syndrome
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Table 5.4: The genes that have the strongest interaction as well as the diseases that have
the strongest association with top 23 ranked genes selected by EDIL-W when α = 1.5
Rank Gene Degree The most in-
teracted gene
The most associated disease
6 BRAF 463 PTPN11 noonan syndrome
7 POMC 296 COL2A1 obesity
8 TBX1 204 COMT digeorge syndrome
9 FGFR1 345 FGFR2 kallmann syndrome
10 APOE 261 LDLR alzheimer’s disease
11 FBN1 241 TGFBR2 marfan syndrome
12 POLG 412 TYMP alpers syndrome
13 ALMS1391 DICER1 alstrom syndrome
14 ELN 347 FBLN5 supravalvular aortic stenosis
15 ERCC6532 ERCC8 cockayne syndrome, type ii
16 TGFB1277 TNF camurati-engelmann syndrome
17 FLNA 381 FBN1 oto-palato-digital syndrome type 1
18 GNAS 397 STX16 pseudohypoparathyroidism, type ia
19 COL2A199 COL11A2 platyspondylic lethal skeletal dysplasia,
torrance type
20 IL6 346 TNF rheumatoid arthritis, systemic juvenile
21 FGFR3 304 FGFR2 muenke syndrome
22 INS 384 KCNJ11 diabetes mellitus, permanent neonatal
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Table 5.4: The genes that have the strongest interaction as well as the diseases that have
the strongest association with top 23 ranked genes selected by EDIL-W when α = 1.5
Rank Gene Degree The most in-
teracted gene
The most associated disease
23 IL1B 293 KCNJ11 alzheimer’s disease
The DAVID application gives us 560 recodes. Because of the large number of
records, we filter the records by ignoring some annotation categories including COG-
ONTOLOGY, SP-PIR-KEYWORDS, and UP-SEQ-FEATURE. In addition, we set
arbitrary a minimum number of genes involved in the corresponding term as 7. Then,
48 annotation terms and their related genes are sorted by p-value from top to bottom
(Table 5.5). The low p-value confirms the importance of our findings.
Table 5.5: Functional annotation chart of top 23 ranked genes selected by EDIL-W with
α = 1.5
Term Genes p-
Value
regulation of protein kinase cas-
cade
ERCC6, FLNA, INS, IL1B, IL6,
PTEN, TGFB1, TNF
8.9E-8
MAPKKK cascade ERCC6, FGFR1, FGFR3, INS,
IL1B, TNF, BRAF
3.6E-7
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Table 5.5: Functional annotation chart of top 23 ranked genes selected by EDIL-W with
α = 1.5
Term Genes p-
Value
skeletal system development GNAS, TBX1, COL2A1, FBN1,
FGFR1, FGFR3, INS, TGFB1
4.8E-7
negative regulation of apoptosis COL2A1, APOE, INS, IL1B, IL6,
PTEN, TNF, BRAF
9.6E-7
negative regulation of pro-
grammed cell death
COL2A1, APOE, INS, IL1B, IL6,
PTEN, TNF, BRAF
1.1E-6
negative regulation of cell death COL2A1, APOE, INS, IL1B, IL6,
PTEN, TNF, BRAF
1.1E-6
positive regulation of transport FLNA, APOE, INS, IL1B, IL6,
TGFB1, TNF
1.1E-6
transmembrane receptor protein
tyrosine kinase signaling pathway
FGFR1, FGFR2, FGFR3, FLNA,
INS, PTEN, TGFB1
1.2E-6
regulation of cell proliferation FGFR1, FGFR2, FGFR3, APOE,
INS, IL1B, IL6, PTEN, TGFB1,
TNF
1.8E-6
regulation of apoptosis COL2A1, ERCC6, APOE, INS,
IL1B, IL6, PTEN, TGFB1, TNF,
BRAF
2.2E-6
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Table 5.5: Functional annotation chart of top 23 ranked genes selected by EDIL-W with
α = 1.5
Term Genes p-
Value
regulation of programmed cell
death
COL2A1, ERCC6, APOE, INS,
IL1B, IL6, PTEN, TGFB1, TNF,
BRAF
2.4E-6
regulation of cell death COL2A1, ERCC6, APOE, INS,
IL1B, IL6, PTEN, TGFB1, TNF,
BRAF
2.4E-6
positive regulation of cell prolifer-
ation
FGFR1, FGFR2, FGFR3, INS,
IL1B, IL6, TGFB1, TNF
2.7E-6
regulation of phosphorylation ERCC6, APOE, INS, IL1B, IL6,
PTEN, TGFB1, TNF
6.0E-6
regulation of phosphorus
metabolic process
ERCC6, APOE, INS, IL1B, IL6,
PTEN, TGFB1, TNF
7.8E-6
regulation of phosphate
metabolic process
ERCC6, APOE, INS, IL1B, IL6,
PTEN, TGFB1, TNF
7.8E-6
intracellular signaling cascade ALMS1, GNAS, ERCC6, FGFR1,
FGFR3, FLNA, APOE, INS, IL1B,
TNF, BRAF
1.0E-5
MAPK signaling pathway FGFR1, FGFR2, FGFR3, FLNA,
IL1B, TGFB1, TNF, BRAF
1.3E-5
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Table 5.5: Functional annotation chart of top 23 ranked genes selected by EDIL-W with
α = 1.5
Term Genes p-
Value
enzyme linked receptor protein
signaling pathway
FGFR1, FGFR2, FGFR3, FLNA,
INS, PTEN, TGFB1
1.3E-5
regulation of protein kinase activ-
ity
ERCC6, APOE, INS, IL1B, PTEN,
TGFB1, TNF
1.4E-5
extracellular region GNAS, COL2A1, ELN, FBN1,
FGFR2, FLNA, APOE, INS, IL1B,
IL6, POMC, TGFB1, TNF
1.6E-5
regulation of kinase activity ERCC6, APOE, INS, IL1B, PTEN,
TGFB1, TNF
1.7E-5
response to hormone stimulus GNAS, INS, IL1B, IL6, PTEN,
TGFB1, TNF
2.0E-5
protein kinase cascade ERCC6, FGFR1, FGFR3, INS,
IL1B, TNF, BRAF
2.1E-5
regulation of transferase activity ERCC6, APOE, INS, IL1B, PTEN,
TGFB1, TNF
2.1E-5
positive regulation of molecular
function
GNAS, ERCC6, APOE, INS, IL1B,
IL6, TGFB1, TNF
2.7E-5
response to endogenous stimulus GNAS, INS, IL1B, IL6, PTEN,
TGFB1, TNF
3.4E-5
78
Table 5.5: Functional annotation chart of top 23 ranked genes selected by EDIL-W with
α = 1.5
Term Genes p-
Value
identical protein binding GNAS, TBX1, COL2A1, FGFR3,
FLNA, APOE, TGFB1, TNF
4.3E-5
positive regulation of nitrogen
compound metabolic process
TBX1, ERCC6, APOE, INS, IL1B,
IL6, TGFB1, TNF
4.9E-5
protein amino acid phosphoryla-
tion
ERCC6, FGFR1, FGFR2, FGFR3,
IL1B, TGFB1, TNF, BRAF
6.1E-5
extracellular space COL2A1, FBN1, APOE, INS, IL1B,
IL6, TGFB1, TNF
7.4E-5
extracellular region part COL2A1, ELN, FBN1, APOE, INS,
IL1B, IL6, TGFB1, TNF
8.3E-5
regulation of cellular protein
metabolic process
ERCC6, APOE, INS, IL1B, IL6,
TGFB1, TNF
8.3E-5
phosphate metabolic process ERCC6, FGFR1, FGFR2, FGFR3,
IL1B, PTEN, TGFB1, TNF, BRAF
9.0E-5
response to organic substance GNAS, APOE, INS, IL1B, IL6,
PTEN, TGFB1, TNF
1.0E-4
positive regulation of catalytic ac-
tivity
GNAS, ERCC6, APOE, INS, IL1B,
TGFB1, TNF
1.4E-4
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Table 5.5: Functional annotation chart of top 23 ranked genes selected by EDIL-W with
α = 1.5
Term Genes p-
Value
phosphorylation ERCC6, FGFR1, FGFR2, FGFR3,
IL1B, TGFB1, TNF, BRAF
1.9E-4
positive regulation of macro-
molecule metabolic process
TBX1, ERCC6, APOE, INS, IL1B,
IL6, TGFB1, TNF
2.9E-4
positive regulation of nucleobase,
nucleoside, nucleotide and nucleic
acid metabolic process
TBX1, ERCC6, APOE, INS, IL6,
TGFB1, TNF
3.7E-4
neurological system process ALMS1, GNAS, TBX1, COL2A1,
ERCC6, APOE, IL1B, PTEN,
TGFB1
4.1E-4
pathways in cancer FGFR1, FGFR2, FGFR3, IL6,
PTEN, TGFB1, BRAF
4.6E-4
positive regulation of cellular
biosynthetic process
TBX1, APOE, INS, IL1B, IL6,
TGFB1, TNF
6.1E-4
positive regulation of biosynthetic
process
TBX1, APOE, INS, IL1B, IL6,
TGFB1, TNF
6.6E-4
cell death ALMS1, INS, IL1B, IL6, PTEN,
TGFB1, TNF
7.9E-4
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Table 5.5: Functional annotation chart of top 23 ranked genes selected by EDIL-W with
α = 1.5
Term Genes p-
Value
death ALMS1, INS, IL1B, IL6, PTEN,
TGFB1, TNF
8.2E-4
homeostatic process ALMS1, COL2A1, APOE, INS,
IL1B, IL6, TGFB1
9.9E-4
cell surface receptor linked signal
transduction
GNAS, FGFR1, FGFR2, FGFR3,
FLNA, APOE, INS, PTEN, POMC,
TGFB1
1.6E-3
cognition ALMS1, GNAS, TBX1, COL2A1,
ERCC6, IL1B, PTEN
2.7E-3
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Conclusion
To conclude, we construct a weighted gene-disease bipartite network to represent
the associations among genes and diseases. Then, we construct two new networks,
called the weighted human disease network (WHDN) and the weighted gene network
(WGN). In addition, we propose a new centrality measure, called DIL-W, to find the
most important diseases in the WHDN and extend the DIL-W method, called EDIL-
W, to identify the most important genes in the WGN. Our network-based analysis
methods are shown to be able to identify more important diseases and genes in terms
of network efficiency compared to degree, closeness, and betweenness centralities.
The identified disease-disease correlations include previous knowledge supported by
published literature as well as less known and novel correlations that can be valuable
for future studies. Meanwhile, the identified gene-gene interactions are supported by
DAVID through functional annotation and enrichment analysis.
Our understanding of complex human diseases is still largely unclear, and the
disease-gene associations are far from being complete. Future studies could explore
the utilization of multiple types of data and more powerful computational tools to
better cluster and categorize human diseases and to predict new genes and other
factors that can explain diseases.
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